Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) can be used safely by many people with high blood pressure, and clinical trial data suggest it may actually help lower blood pressure over time as weight falls. That said, semaglutide is a prescription-only medicine requiring full clinical assessment before anyone starts it — a prescriber reviews your cardiovascular history, current medications and overall health picture, not just your BMI. The common worry is that a weight-loss injection might worsen blood pressure or interact badly with antihypertensives; the evidence, and the NHS's own guidance, tells a more reassuring story, but there are still real nuances worth understanding before you decide. Our full side-effect profile for Wegovy covers the broader picture if you want the wider context alongside this.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A concern that comes up often is whether starting a weight-loss injection could put additional strain on the heart or push blood pressure higher. It is an understandable worry, particularly for people already managing hypertension with medication. The trial evidence does not support that fear as a general pattern. In the STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo, published in the New England Journal of Medicine) participants on semaglutide saw modest reductions in systolic blood pressure on average. The most likely explanation is straightforward: carrying less weight places less demand on the circulatory system, and the medicine drives meaningful weight loss.
Semaglutide itself does cause a small, modest increase in resting heart rate in some people — typically around one to four beats per minute in trials. For most individuals this is clinically unremarkable, but it is a real effect and one your prescriber factors into the assessment if you have an arrhythmia or other heart-rhythm condition. The NHS medicines information for semaglutide notes this in its list of less common effects. So the headline is not that Wegovy is dangerous for high blood pressure, it is that the picture is more detailed than a simple yes or no.
Having high blood pressure does not automatically rule Wegovy out. Many of the participants enrolled in the STEP trials had existing cardiovascular risk factors, which is precisely why Wegovy later gained a UK authorisation for reducing major cardiovascular event risk in eligible adults. What matters is the full clinical picture. People whose blood pressure is very poorly controlled, whose antihypertensive regimen is complex, or who have heart failure or significant arrhythmias will need a more careful conversation with a prescriber before starting.
There is also a practical consideration once treatment is working: if your blood pressure falls as your weight falls, your existing blood pressure medication may need adjusting over time. That is not a problem unique to Wegovy (it is true of any effective weight-loss treatment) but it means staying in contact with your GP throughout. How Wegovy affects blood pressure in more detail is covered on its own page if you want the clinical specifics. And if you are weighing up whether this medicine is appropriate for your situation overall, our broader Wegovy safety overview is a useful companion read.
Most people starting Wegovy notice side effects that are gastrointestinal (nausea, loose stools, indigestion, that sort of thing) which tend to settle within the first couple of weeks at each dose level. Blood-pressure-specific warning signs are a separate category and deserve clarity. Seek emergency medical attention immediately for any of the following: a sudden severe headache unlike any you have had before, blurred or disturbed vision, chest pain, difficulty breathing, or a feeling that something is seriously wrong. These can be signs of a hypertensive crisis or a cardiac event, and they need a 999 call, not a wait-and-see approach.
Also contact your prescriber or GP promptly (rather than urgently) if you notice your home blood pressure readings rising noticeably after starting semaglutide, if you feel your heart racing or skipping beats in a way that concerns you, or if you feel faint or dizzy on standing. Dizziness on standing can sometimes indicate that blood pressure medication is now doing more than it needs to as your weight drops. In January 2026 the MHRA issued a Drug Safety Update reminding patients and clinicians that GLP-1 medicines carry a risk of acute pancreatitis; severe, persistent stomach pain spreading to the back is a reason to seek same-day medical attention. You should also be aware that vomiting blood while taking Wegovy is a serious symptom, and our page on what to do if you experience Wegovy vomiting blood explains when this warrants emergency care. You can report any suspected side effects (from any medicine) directly to the MHRA via the Yellow Card scheme.
One practical note: keeping Wegovy at 2–8°C until you use it (the fridge door works well for most people) preserves the medicine properly and means you are always taking it as tested. The patient information leaflet that comes with your pen is the definitive guide to storage windows at room temperature.
Because semaglutide is a prescription-only medicine, no one at nume starts treatment without a GPhC-registered Independent Prescriber personally reviewing the full consultation. Blood pressure history, current medications including antihypertensives, and any cardiac conditions are all part of what they read before making a clinical decision. There is no algorithmic shortcut. If a prescriber considers that treatment needs further input from your GP or cardiologist first, they say so plainly. The clinical team is there to make the right call, not to approve everyone who applies.
If you want to understand more about whether Wegovy could be clinically appropriate for you, a free consultation is the right starting point. You can also explore what the treatment journey looks like on our Wegovy overview page, or compare options through the weight-loss treatment guide. Questions about cost sit on our Wegovy cost page if that is useful context. When you are ready, speak to our prescribers about your situation, including your blood pressure history, as part of the consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.